Page 5 - Alteogen Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Intas Pharma inks licensing agreement with Korean firm to develop new products
Intas Pharma inks licensing agreement with Korean firm to develop new products
08 January 2021 | News
Alteogen will receive an initial payment of $6 million and is also eligible to receive additional milestones upon Intas’ achievement of specified development, regulatory and sales milestones, totalling up to $109 million
Source credit: Shutterstock
South Korean firm Alteogen Inc has announced that it has entered into an exclusive license agreement with Ahmedabad based Intas Pharmaceuticals Ltd to use ALT-B4, Alteogen’s novel hyaluronidase – derived utilising the Hybrozyme™ technology – to develop and commercialise two products.
Under the terms of the agreement, Alteogen has granted worldwide rights, except for a few Asian countries, for Intas to develop two products in combination with ALT-B4. Alteogen will receive an initial payment of $6 million and is also e ....

South Korea , South Korean , Binish Chudgar , Intas Pharmaceuticals , Intas Pharmaceuticals Ltd , Alteogen Inc , Soon Jae Park , Chief Executive Officer , Vice Chairman , தெற்கு கொரியா , தெற்கு கொரியன் , இன்டாஸ் மருந்துகள் , இன்டாஸ் மருந்துகள் லிமிடெட் , விரைவில் ஜே பூங்கா , தலைமை நிர்வாகி அதிகாரி , துணை தலைவர் ,